Nordion cancer, supply/service news
Nordion restructured to form two business units, effective Nov. 1. Nordion said the move is designed to take into account the unique product life cycles and customer needs in each of the businesses. A targeted therapies unit will supply cancer therapies, including Nordion's TheraSphere, and offer radiopharmaceutical development and clinical/commercial manufacturing services. A specialty isotopes unit will include two supply/service segments, one for sterilization techniques and another for medical isotopes. Scott McIntosh, formerly SVP of operations at Nordion, will become COO of the specialty isotopes unit, while Steve West, CEO of Nordion, will act as interim COO of the targeted therapies unit. As a result of the restructuring, Kevin Brooks, SVP of sales and marketing, and Peter Covitz, SVP of innovation, will depart. ...